Soufflé Therapeutics raised $135 million in venture capital to advance at least three experimental oligonucleotide medicines. The funding adds to momentum in RNA therapeutics that emphasize delivery, targeting, and manufacturing feasibility to expand beyond a single lead candidate. For investors and biotech operators, the key signal is scale: multi-asset capitalization typically supports faster selection across candidates and accelerates IND-enabling work across separate MOAs or delivery strategies.